Media stories about Sophiris Bio (NASDAQ:SPHS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sophiris Bio earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.4875280582287 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Analysts See $-0.10 EPS for Sophiris Bio, Inc. (SPHS) – Gоldmаn Blоg (blog) (goldmanblog.com)
- Sophiris Bio (SPHS) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- Sophiris Bio to Present at 17th Annual Needham Healthcare … – Markets Insider (markets.businessinsider.com)
- Sophiris Bio, Inc. (SPHS) EPS Estimated At $-0.10 – Gоldmаn Blоg (blog) (goldmanblog.com)
- Sophiris Bio Inc (SPHS) Expected to Post Earnings of -$0.10 Per Share (americanbankingnews.com)
Sophiris Bio (NASDAQ SPHS) remained flat at $$2.12 during mid-day trading on Tuesday. The company’s stock had a trading volume of 42,357 shares, compared to its average volume of 199,967. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. The stock has a market cap of $65.64, a P/E ratio of -11.78 and a beta of 1.30. Sophiris Bio has a 1 year low of $1.80 and a 1 year high of $2.95.
Several research analysts have weighed in on SPHS shares. ValuEngine upgraded Sophiris Bio from a “strong sell” rating to a “sell” rating in a research report on Friday, December 15th. HC Wainwright set a $6.00 price objective on Sophiris Bio and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Maxim Group reiterated a “buy” rating and set a $5.00 price objective (down previously from $6.00) on shares of Sophiris Bio in a research report on Wednesday, February 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $6.00.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.